Novel preventative strategies against invasive aspergillosis

Medical Mycology

Volumn 44, Issue SUPPL. 1, 2006, Pages 327-332

  Mantadakis, Elpis ^a   Samonis, George ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Chemoprophylaxis; Hematopoietic stem cell transplantation; Invasive aspergillosis

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; CASPOFUNGIN; CORTICOSTEROID; ECHINOCANDIN; FLUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; VORICONAZOLE;

AIR QUALITY STANDARD; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIBIOTIC RESISTANCE; ARTICLE; ASPERGILLOSIS; ASPERGILLUS; AUTOTRANSPLANTATION; CANDIDIASIS; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE PREDISPOSITION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FILTRATION; FUNGAL CONTAMINATION; FUNGAL STRAIN; FUNGUS TRANSMISSION; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HIGH RISK POPULATION; HOSPITAL INFECTION; HUMAN; IMMUNE DEFICIENCY; INFECTION RISK; META ANALYSIS; MORTALITY; NONHUMAN; PRIMARY PREVENTION; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SECONDARY PREVENTION; SYSTEMATIC REVIEW;

ASPERGILLUS; FUNGI;

EID: 33749511425     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.1080/13693780600849113     Document Type: Article

References (29)

1. Singh, N. (2001) Trends in the epidemiology of opportunistic fungal infections: Predisposing factors and the impact of antimicrobial use practices Clin Infect Dis, 33, pp. 1692-1696.
2. McNeil, MM and Nash, SL and Hajjeh, RA and (2001) Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997 Clin Infect Dis, 33, pp. 641-647.
3. Kontoyiannis, DP and Mantadakis, E and Samonis, G. (2003) Systemic mycoses in the immunocompromised host: An update in antifungal therapy J Hosp Infect, 53, pp. 243-258.
4. Warris, A and Verweij, PE. (2005) Clinical implications of environmental sources for Aspergillus Med Mycol, 43(Suppl 1), pp. S59-S65.
5. Ascioglu, S and de Pauw, BE and Meis, JF. (2000) Prophylaxis and treatment of fungal infections associated with haematological malignancies Int J Antimicrob Agents, 15, pp. 159-168.
6. Sherertz, RJ and Belani, A and Kramer, BS and (1987) Impact of air filtration on nosocomial Aspergillus infections. Unique risk of bone marrow transplant recipients Am J Med, 83, pp. 709-718.
7. Hahn, T and Cummings, KM and Michalek, AM and (2002) Efficacy of HEPA filters in preventing aspergillosis in immunocompromised patients with hematologic malignancies Infect Control Hosp Epidemiol, 23, pp. 525-531.
8. Almyroudis, NG and Fuller, A and Jakubowski, A and (2005) Pre- and post-engraftment bloodstream infection rates and associated mortality in allogeneic hematopoietic stem cell transplant recipients Transpl Infect Dis, 7, pp. 11-17.
9. Hamza, NS and Ghannoum, MA and Lazarus, HM. (2004) Choices aplenty: antifungal prophylaxis in hematopoietic stem cell transplant recipients Bone Marrow Transplant, 34, pp. 377-389.
10. Marr, KA and Carter, RA and Boeckh, M and (2002) Invasive aspergillosis in allogeneic stem cell transplant recipients: Changes in epidemiology and risk factors Blood, 100, pp. 4358-4366.
11. Wingard, JR and Leather, H. (2004) A new era of antifungal therapy Biol Blood Marrow Transplant, 10, pp. 73-90.
12. Martino, R and Subira, M and Rovira, M and (2002) alloPBSCT Infectious/ Non-infectious Complications Subcommittees of the Grupo Espanol de Trasplante Hematopoyetico (GETH). Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: Incidence and risk factors in 395 patients Br J Haematol, 116, pp. 475-482.
13. Thursky, K and Byrnes, G and Grigg, A and (2004) Risk factors for post-engraftment invasive aspergillosis in allogeneic stem cell transplantation Bone Marrow Transplant, 34, pp. 115-121.
14. Prentice, AG and Glasmacher, A and Djulbegovic, B. (2006) In meta-analysis itraconazole is superior to fluconazole for prophylaxis of systemic fungal infection in the treatment of haematological malignancy Br J Haematol, 132, pp. 656-659.
15. Glasmacher, A and Prentice, A and Gorschluter, M and (2003) Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: Evidence from a meta-analysis of 3597 patients J Clin Oncol, 21, pp. 4615-4626.
16. Mattiuzzi, GN and Kantarjian, H and O'Brien, S and (2004) Intravenous itraconazole for prophylaxis of systemic fungal infections in patients with acute myelogenous leukemia and high-risk myelodysplastic syndrome undergoing induction chemotherapy Cancer, 100, pp. 568-573.
17. Kontoyiannis, DP and Bodey, GP. (2002) Invasive aspergillosis in 2002: an update Eur J Clin Microbiol Infect Dis, 21, pp. 161-172.
18. PenackO, ReinwaldM, Schmidt-HieberM,. Low dose liposomal amphotericin B as prophylaxis of invasive fungal infections in patients with prolonged neutropenia: Results from a Rhase-III trialIn:Program and abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, 16-19December2005: Abstract M-975HerndonVA: ASM Press.
19. Glasmacher, A and Molitor, E and Hahn, C and (1998) Antifungal prophylaxis with itraconazole in neutropenic patients with acute leukaemia Leukemia, 12, pp. 1338-1343.
20. Morgenstern, G and Prentice, AG and Prentice, HG and (1999) A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies Br J Haematol, 105, pp. 901-911.
21. Winston, DJ and Maziarz, RT and Chandrasekar, PH and (2003) Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial Ann Intern Med, 138, pp. 705-713.
22. Glasmacher, A and Cornely, O and Ullmann, AJ and (2006) on behalf of the Itraconazole Research Group of Germany. An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia J Antimicrob Chemother, 57, pp. 317-325.
23. Ullmann AJ, Lipton JH, Vesole DH. Posaconazole vs. fluconazole for prophylaxis of invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease: Results of a multicenter trial. In: Program and abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, 16-19December2005: Abstract M-716HerndonVA: ASM Press.
24. CornelyO, MaertensJ, WinstonD,. Posaconazole vs. standard azole therapy for prophylaxis of invasive fungal infections among high-risk neutropenic patients: Results of a randomized, multicenter trial. In: Program and abstracts of the 47th American Society of Hematology, Atlanta, Georgia, 10-13December2005: Abstract 1844WashingtonDC: ASM Press.
25. Mattiuzzi, GN and Alvarado, G and Giles, FJ and (2006) Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies Antimicrob Agents Chemother, 50, pp. 143-147.
26. van Burik, JA and Ratanatharathorn, V and Stepan, DE and (2004) for the National Institute of Allergy and Infectious Diseases Mycoses Study Group. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation Clin Infect Dis, 39, pp. 1407-1416.
27. CornelyOA, MartinoR, MaschmeyerG,. Efficacy of caspofungin as secondary antifungal prophylaxis for prevention of breakthrough fungal infection: data from a multinational case registry. In: Program and abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, 16-19December2005: Abstract M-957HerndonVA: ASM Press.
28. Cordonnier, C and Maury, S and Pautas, C and (2004) Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients Bone Marrow Transplant, 33, pp. 943-948.
29. Glasmacher, A and Prentice, AG. (2005) Evidence-based review of antifungal prophylaxis in neutropenic patients with haematological malignancies J Antimicrob Chemother, 56(Suppl 1), pp. i23-i32.